AEGIS MEDICAL TECHNOLOGIES DEVELOPING SUPER-COLD CATHETER IN CRADA
This article was originally published in The Gray Sheet
AEGIS MEDICAL TECHNOLOGIES DEVELOPING SUPER-COLD CATHETER IN CRADA with the National Institute of Standards and Technology. Aegis hopes by year end to have a prototype, or at least "proof of concept," of the catheter, which could be used for cryosurgery, ablation therapy, and treatment of arrhythmias. Aegis has already filed for one patent for the cold-catheter technology, the company says.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.